News Release Details

Talaris Therapeutics to Participate at Three Upcoming Virtual Investor Conferences

November 08, 2021

BOSTON and LOUISVILLE, Ky., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that members of its senior management team will participate at the following investor conferences:

Virtual Guggenheim 3rd Annual Neuro/Immunology Conference
Dates: November 15-16, 2021
1x1 meetings only
 
Stifel 2021 Virtual Healthcare Conference
Presentation date: Monday, November 15, 2021
Presentation time: 11:20 a.m. ET
 
Evercore ISI 4th Annual HealthCONx Virtual Conference
Fireside Chat Date: Thursday, December 2, 2021
Fireside Chat Time: 10:05 a.m. ET

A live webcast of the presentation at the Stifel 2021 Virtual Healthcare Conference and the fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference will be available on the investors section of the Talaris website at www.talaristx.com. After the live webcast, a replay of the events can be found on the Talaris website.

About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage biopharmaceutical company developing investigational, one-time, allogeneic cell therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders. Talaris maintains corporate offices in Boston, MA, and its cell processing facility in Louisville, KY. For additional information, visit talaristx.com, and follow Talaris on TwitterLinkedIn and Facebook.

Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783

Investor Contact
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
(339) 970-2843


Print Page
RSS Feeds
Email Alerts
Email Page